Protein Degradation
With 19 new drugs entering the clinic and 185 new degrader developers emerging in 2024 alone, and the field waiting with bated breadth for the first targeted protein degrader expected to gain commercial approval in 2025, the induced proximity field continues to experience rapid growth, reflecting the potential of these modalities to target the previously undruggable.
Our mission is to supercharge the development and approval of first- and best-in-class selective, safe and clinically efficacious degraders and proximity-based drugs for patients in need.
Bringing Best-in-Class Proximity-Based Therapies to Patients Faster
As protein degraders and molecular glues advance through clinical trials to approval, proximity-based modalities have undergone a wave of innovation and investment. The field is expanding with respect to not only chemical space but also biological – from new degraders targeting the endosome & autophagy pathways to protein stabilization and post-translational modification.
From the industry’s definitive conferences to curated clinical trial, drug and company database solutions, we provide valuable insights and meaningful connections to accelerate the path of best-in-class degraders and induced proximity-based therapeutics through the clinic and to commercial success.
We work with the leading innovators in the degrader field to bring clarity to the complexity of small molecule drug development, enabling you to stay up-to-date with scientific advancements and solve shared challenges to deliver targeted proximity-based therapeutics to tackle unmet medical needs.
Featured Protein Degradation Products
Protein Degradation Products by Type
CONTACT US
Get in touch
We speak to hundreds of biopharmaceutical experts from industry and academia every day. We would love for you to be one of them. Contact us to discover how our events can accelerate your drug development.
Standard Form - Protein Degradation
"*" indicates required fields